Results 321 to 330 of about 857,003 (376)

Clinical Pharmacology of the Antibody-Drug Conjugate Enfortumab Vedotin in Advanced Urothelial Carcinoma and Other Malignant Solid Tumors. [PDF]

Clin Pharmacokinet
Tang M, Garg A, Bonate PL, Rosenberg JE, Matsangou M, Kadokura T, Yamada A, Choules M, Pavese J, Nagata M, Tenmizu D, Koibuchi A, Heo N, Wang L, Wojtkowski T, Hanley WD, Poondru S.   +16 more
europepmc   +1 more source

Model-Informed Clinical Pharmacology Profile of a Novel Fixed-Dose Combination of Nivolumab and Relatlimab in Adult and Adolescent Patients with Solid Tumors. [PDF]

Clin Cancer Res
Zhao Y, Hu Z, Bathena SP, Keidel S, Miller-Moslin K, Statkevich P, Bello A, Roy A, Suryawanshi S.   +8 more
europepmc   +1 more source

Advancing Precision Medicine: A Review of Innovative In Silico Approaches for Drug Development, Clinical Pharmacology and Personalized Healthcare. [PDF]

Pharmaceutics
Marques L, Costa B, Pereira M, Silva A, Santos J, Saldanha L, Silva I, Magalhães P, Schmidt S, Vale N.   +9 more
europepmc   +1 more source

Clinical Pharmacology of Cilazapril [PDF]

Drugs, 1989
In clinical pharmacology studies, cilazapril, after its bioactivation to cilazaprilat, was characterised as a potent, reversible angiotensin converting enzyme (ACE) inhibitor with a terminal half-life of 30 to 50 hours, which is consistent with saturable binding to ACE.
Ulf-W. Wiegand, Cornelis H. Kleinbloesem, Robert J. Francis, Peter Van Brummelen   +3 more
openaire   +3 more sources

Pharmacology and Clinical Pharmacology of Vigabatrin [PDF]

Journal of Child Neurology, 1991
Vigabatrin is an enzyme-activated, irreversible inhibitor of γ-aminobutyric acid (GABA) aminotransferase, which causes a marked increase in cerebral GABA concentration and a resulting anticonvulsant action. Recovery from its effects requires the synthesis of new enzyme, and this may take several days following a single dose.
openaire   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Clinical Pharmacology

DeckerMed Surgery, 2020
Critically ill patients often require surgical procedures and therapeutic interventions that produce significant pathophysiologic changes. Drug pharmacology can be greatly altered in this population wherein comorbid diseases, varied organ function, and polypharmacy can produce adverse drug reactions (ADRs).
Eric W. Mueller, Molly Droege
openaire   +1 more source

Clinical pharmacology of progestins

Minerva Obstetrics and Gynecology, 2022
In this paper, we report general pharmacological profile and major biological activities of natural progesterone (P) and progestins. The aim of this article consists of synthesizing the principal aspects of pharmacology and metabolism of P and progestins related to the clinical consequences of their use.We review scientific literature on the topic ...
Capozzi, Anna, Scambia, Giovanni, Lello, Stefano   +2 more
openaire   +3 more sources

Clinical Pharmacology

JAMA: The Journal of the American Medical Association, 1989
The issue of what drug effects to measure, surrogate end points, has been emphasized by two recent clinical trials. Several recent studies have given us new information about why different people react so differently to the same dose of the same medicine.
openaire   +5 more sources

Clinical Pharmacology of Inodilators

Journal of Cardiovascular Pharmacology, 1989
Recent advances in our knowledge of heart failure have shown that both a central and a peripheral factor are involved in this syndrome. Therefore, the ideal drug should combine the properties of a positive inotropic agent with those of a peripheral vasodilator; many drugs recently introduced into clinical practice have been shown to present both of ...
DEI CAS, Livio, METRA, Marco, VISIOLI, Odoardo   +2 more
openaire   +4 more sources